#Liver Disease Diagnostics Market Growth

[industrynewsupdates]

Liver Disease Diagnostics Market Size, Share And Trends Analysis Report

The global liver disease diagnostics market size is expected to reach USD 55.58 billion by 2030, expanding at a CAGR of 6.61% from 2024 to 2030, according to a new report by Grand View Research, Inc. increasing funding and research initiatives undertaken by market players is one of the major factors expected to propel market growth. For instance, in November 2019, Glycotest, Inc. received the second USD 3.0 million tranche of USD 10.0 million Series A funding from Shanghai Fosun Pharmaceutical Co., Ltd.(Fosun Pharma). Under this investment, Glycotest, Inc. transferred HCC panel technology to Fosun Pharma to commercialize in China and develop tests for liver cancer and liver fibrosis that are currently under pipeline.

Companies are focusing on collaborations and partnership to improve the quality of care,which is anticipated to drive the market. For instance, in October 2019, Perspectum Diagnostics entered into a partnership to offer LiverMultiScan at Precious Medical Center in Singapore. The aim of this partnership was to create awareness among people to consider liver checking as an integral part of their health screening.

Researchers conducting studies to support the development of novel diagnostic methods that can accurately differentiate between benign and malignant lesions are expected to fuel market growth. For instance, researchers from Charité - Universitätsmedizin Berlin used tomoelastography to visualize mechanical properties of tumors and developed a new Magnetic Resonance Imaging (MRI) technique to detect grading of tumor consistency.

Gather more insights about the market drivers, restrains and growth of the Liver Disease Diagnostics Market

Liver Disease Diagnostics Market Report Highlights

• The imaging segment accounted for the largest revenue share and is expected to grow at the fastest CAGR. This is attributed to the rising number of initiatives taken by key players in the liver disease diagnostics market to develop advanced imaging techniques.

• The hospitals segment held the largest revenue share of around 45.07% in 2023 as the majority of patients rely on hospitals well-equipped with diagnostic testing devices.

• North America dominated the market and accounted for the largest revenue share of over 41.71% in 2023 followed by Europe. High investments in R&D and the presence of key players are some factors expected to be responsible for the growth of the market for liver disease diagnostics in the region.

• Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Increasing geriatric population and awareness about regular check-ups are contributing to the growth of the market for liver disease diagnostics in this region.

Liver Disease Diagnostics Market Segmentation

Grand View Research has segmented the global liver disease diagnostics market on the basis of diagnosis technique, disease, end use, and region:

Liver Disease Diagnostics Diagnosis Technique Outlook (Revenue, USD Million, 2018 - 2030)

• Laboratory Tests

• Imaging

• Endoscopy

• Biopsy

• Others

Liver Disease Diagnostics Disease Outlook (Revenue, USD Million, 2018 - 2030)

• NAFLD

• NASH

• Fibrosis

• Cirrhosis

• HCC

• Others

Liver Disease Diagnostics End use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Laboratories

• Others

Liver Disease Diagnostics Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Norway

o Denmark

o Sweden

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Liver Disease Diagnostics Market Intelligence Study, published by Grand View Research.

[mordorintelligencemarketresearch]

The Albumin Industry: A Vital Component in Healthcare and Biopharmaceuticals 

Albumin, a vital protein found in blood plasma, has become an indispensable resource in the healthcare and biopharmaceutical industries. Known for its versatility and wide-ranging applications, albumin serves critical roles in medical treatments, drug delivery systems, and diagnostics. Its increasing demand across healthcare systems worldwide underscores its importance in addressing diverse clinical needs, from treating life-threatening conditions like hypovolemia and shock to enabling advanced drug formulations in biopharmaceuticals. 

The albumin market is projected to reach a value of USD 7.27 billion in 2024 and is anticipated to grow to USD 10.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.76% over the forecast period from 2024 to 2029. 

Understanding Albumin and Its Importance 

Albumin, primarily derived from human plasma, is a key protein responsible for maintaining oncotic pressure and fluid balance in the body. It also serves as a carrier for hormones, enzymes, drugs, and other vital substances. In the medical field, albumin is used to treat various conditions, including: 

Hypovolemia: Restoring blood volume in cases of severe fluid loss. 

Hypoproteinemia: Managing low protein levels due to liver or kidney diseases. 

Burns and Trauma: Providing nutritional and osmotic support during recovery. 

Neonatal Conditions: Addressing complications in premature infants. 

Beyond its therapeutic use, albumin is widely employed in research and drug formulation as a stabilizer and carrier. Its ability to bind with various molecules makes it an ideal component for drug delivery systems, especially for targeting challenging diseases like cancer and autoimmune disorders. 

Key Drivers of Growth in the Albumin Industry 

1. Rising Incidence of Chronic Diseases and Critical Conditions 

The growing prevalence of chronic diseases such as liver cirrhosis, nephrotic syndrome, and cancer has significantly increased the demand for albumin. These conditions often lead to complications requiring albumin-based therapies. Additionally, the rising number of surgeries, trauma cases, and burn injuries has further fueled the need for albumin in critical care settings. 

2. Expansion of Biopharmaceutical Applications 

Albumin is gaining prominence in the biopharmaceutical sector as a stabilizer in drug formulations and as a carrier for targeted drug delivery. With the increasing development of biologics and biosimilars, albumin's role in enhancing the stability and efficacy of therapeutic agents is driving its adoption. Technologies like albumin-fusion platforms are enabling the creation of long-acting drugs, further expanding its applications in cutting-edge treatments. 

3. Growth in Plasma Fractionation 

Advancements in plasma fractionation technology have improved the efficiency of albumin production, allowing for greater yields and quality. Plasma fractionation remains the primary method for extracting albumin from blood plasma, and innovations in this area have made albumin more accessible to meet growing demand. 

4. Increasing Awareness and Adoption in Emerging Markets 

Developing regions, particularly in Asia-Pacific and Latin America, are witnessing increased adoption of albumin due to rising awareness about its therapeutic benefits. Governments and healthcare organizations in these regions are investing in improved healthcare infrastructure, driving demand for albumin-based treatments. 

5. Regulatory Support and Strategic Partnerships 

Government initiatives and regulatory frameworks supporting plasma-derived therapies have encouraged investments in the albumin market. Furthermore, collaborations between pharmaceutical companies and research institutions are accelerating the development of novel albumin-based products, contributing to market growth. 

Challenges in the Albumin Industry 

1. Limited Plasma Supply 

Albumin production relies heavily on human plasma donations, which are subject to strict regulations and limited availability. The supply-demand gap poses a significant challenge, particularly as global demand for plasma-derived therapies continues to rise. 

2. High Production Costs 

The extraction and purification of albumin through plasma fractionation are resource-intensive processes, contributing to high production costs. These costs can limit the affordability of albumin-based therapies, particularly in low-income regions. 

3. Competition from Synthetic Alternatives 

The development of synthetic or recombinant albumin as an alternative to plasma-derived albumin is gaining traction. While these alternatives offer advantages such as reduced dependency on plasma donations, they also introduce competition that could impact the traditional albumin market. 

4. Stringent Regulatory Requirements 

Albumin production and distribution are subject to rigorous regulatory standards to ensure safety and efficacy. Navigating these regulations can be time-consuming and costly for manufacturers, delaying product approvals and market entry. 

5. Ethical and Supply Chain Concerns 

The ethical considerations surrounding plasma donation, coupled with complex supply chain logistics, present additional challenges. Ensuring a sustainable and ethical plasma supply chain is critical for the long-term growth of the albumin industry. 

Emerging Trends Shaping the Albumin Industry 

1. Recombinant Albumin Development 

Recombinant albumin, produced through genetic engineering, is gaining attention as a sustainable alternative to plasma-derived albumin. It offers advantages such as consistent quality, reduced risk of contamination, and scalability in production. 

2. Integration with Advanced Drug Delivery Systems 

Albumin is increasingly being integrated with nanoparticle-based drug delivery systems to enhance targeted drug delivery. This innovation is particularly relevant in oncology, where albumin-bound drugs like paclitaxel (marketed as Abraxane) have demonstrated improved efficacy and reduced side effects. 

3. Expansion of Albumin in Diagnostics 

In addition to its therapeutic applications, albumin is being explored for use in diagnostic tools, such as in vitro assays and biomarkers for detecting diseases. Its role in diagnostics is expected to expand as research uncovers new applications. 

4. Sustainability and Ethical Plasma Sourcing 

The industry is focusing on creating more sustainable plasma collection practices and ensuring ethical sourcing to meet growing demand. Initiatives to increase plasma donation awareness and streamline collection processes are gaining momentum. 

5. Personalized Medicine and Albumin Fusion Technology 

Albumin fusion technology is enabling the development of personalized therapies by extending the half-life of drugs and optimizing their pharmacokinetics. This trend aligns with the broader movement toward personalized medicine, offering tailored treatment options for patients. 

Conclusion 

The albumin industry is an essential pillar of modern healthcare, addressing critical medical needs while supporting advancements in biopharmaceuticals and diagnostics. As demand for albumin continues to grow, driven by rising chronic disease prevalence, expanding biopharmaceutical applications, and technological innovations, the industry is poised for sustained growth. 

While challenges such as plasma supply limitations and high production costs persist, emerging trends like recombinant albumin and advanced drug delivery systems offer promising solutions. With a focus on sustainability, innovation, and accessibility, the albumin industry is set to play a transformative role in shaping the future of healthcare, ensuring better outcomes for patients worldwide.    For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/albumin-market 

[healthcarediagnosticmarket]

Paper Diagnostics Market Future Growth Insights: Trends and Innovations , Business Insights, Revenue and Forecast from 2024-2033

Straits Research: Paper Diagnostics Market Poised for Significant Growth, Projected to Reach USD 16.17 Billion by 2030

New York, NY - December 17, 2024 – The global paper diagnostics market, valued at USD 8 billion in 2021, is on a steady trajectory of growth and is projected to reach USD 16.17 billion by 2030, growing at a robust Compound Annual Growth Rate (CAGR) of 8.13% during the forecast period (2022–2030), according to a new market research report by Straits Research.

The market for paper diagnostics has witnessed an exponential rise due to its increasing adoption in healthcare, environmental monitoring, and food safety. These diagnostics are cost-effective, easy to use, and require minimal technical expertise, making them ideal for a wide range of applications across different industries.

Market Definition Paper diagnostics refers to diagnostic tools that use paper-based materials, microfluidics, and lateral flow assays to conduct medical tests and analyses. These devices are used for monitoring, diagnosing, and testing various health conditions, environmental parameters, and food quality, offering significant advancements in convenience and efficiency.

Key Trends Shaping the Paper Diagnostics Market

Advancement in Paper-based Microfluidics: The development of paper-based microfluidics is rapidly evolving, offering precision diagnostics with reduced cost and time, which is driving the market’s expansion.

Rise in Point-of-Care Diagnostics: The growing preference for point-of-care (POC) diagnostic solutions is enabling the widespread use of paper diagnostics in both clinical and home settings, further enhancing market demand.

Market Drivers

Rising Prevalence of Chronic Diseases: With the increasing burden of chronic diseases like cancer, liver disorders, and infectious diseases, there is a growing need for affordable, easy-to-use diagnostic tools, thereby driving market growth.

Growing Demand for Home Healthcare: The shift toward home healthcare and self-testing solutions, especially post-pandemic, is fueling the adoption of paper diagnostics.

Market Opportunities

Expansion in Developing Regions: The rapid development of healthcare infrastructure and growing awareness of diagnostic solutions in emerging markets like Asia-Pacific provides significant growth opportunities.

Technological Innovations: Ongoing innovations in paper diagnostics, such as the integration of artificial intelligence and machine learning, could lead to more advanced, accurate, and efficient diagnostic tools.

Market Segmentation The global paper diagnostics market is segmented based on type, product, application, and end-user. The detailed segmentation is as follows:

By Type

Monitoring Devices

Diagnostic Devices

By Product

Dipsticks

Lateral Flow Assays

Paper-Based Microfluidics

By Application

Environmental Monitoring

Clinical Diagnostics

Cancer

Infectious Diseases

Liver Disorders

Others

Food Quality Testing

By End-User

Home Healthcare

Hospitals and Clinics

Assisted Living Healthcare Facilities

For more information on detailed segmentation, please visit this link.

Key Market Players Several leading companies dominate the paper diagnostics market. These include:

Abbott

Bio-Rad Laboratories

Siemens Healthcare Gmbh

Abcam Plc

Chembio Diagnostic Systems Inc.

Acon Laboratories Inc.

FFEI

ARKRAY Inc.

Creative Diagnostics

Regional Insights North America is currently the dominant region in the paper diagnostics market, owing to advanced healthcare systems and early adoption of innovative diagnostic technologies. However, Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by increasing healthcare investments and a growing demand for affordable diagnostic solutions.

Conclusion The paper diagnostics market is experiencing strong growth, driven by the demand for affordable, efficient, and easy-to-use diagnostic solutions across healthcare, environmental monitoring, and food safety sectors. With technological advancements and increasing awareness, the market is expected to continue its upward trajectory through 2030.

For more information or queries, or if you require customization before making a purchase, please visit here.

This press release highlights the promising future of the paper diagnostics market, detailing key trends, drivers, opportunities, and segmentation. The information is essential for stakeholders looking to understand the dynamics of the market and make informed decisions.

About Straits Research

Straits Research is dedicated to providing businesses with the highest quality market research services. With a team of experienced researchers and analysts, we strive to deliver insightful and actionable data that helps our clients make informed decisions about their industry and market. Our customized approach allows us to tailor our research to each client's specific needs and goals, ensuring that they receive the most relevant and valuable insights.

Contact Us

Email: sales@straitsresearch.com

Address: 825 3rd Avenue, New York, NY, USA, 10022

Tel: UK: +44 203 695 0070, USA: +1 646 905 0080

[jameswilliam4u]

Global Hepatitis B Infection Treatment Market Share, Size, Trends, Growth & Forecast | 2024 - 2032

The hepatitis B infection treatment market size attained a value of approximately USD 4.5 billion in 2023. This growth is primarily driven by the rising prevalence of hepatitis B infections and improved diagnostic capabilities. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.6% during the forecast period of 2024-2032, eventually reaching a value of nearly USD 6.1 billion by 2032.

As the global burden of hepatitis B continues to rise, more emphasis is being placed on the development of effective antiviral therapies, improved diagnostic techniques, and better healthcare access. This blog post will delve into the key factors driving the hepatitis B infection treatment market's growth, its segments, trends, and the outlook for the future, including the impact of the COVID-19 pandemic.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/hepatitis-b-infection-treatment-market/requestsample

Hepatitis B Infection Overview

Hepatitis B is a serious viral infection that affects the liver and can lead to long-term health issues such as cirrhosis, liver cancer, and liver failure. The virus is transmitted through contact with the blood or other body fluids of an infected person. According to the World Health Organization (WHO), approximately 296 million people worldwide were living with chronic hepatitis B in 2019. While the number of diagnosed cases continues to rise, advancements in treatment options have significantly improved patient outcomes.

Market Overview: Share and Size

The hepatitis B infection treatment market is currently valued at USD 4.5 billion in 2023. This is due to several factors, including increasing awareness about hepatitis B, advancements in diagnostic tools, and enhanced access to treatment in both developed and developing regions. The market is expected to expand at a CAGR of 3.6% during the forecast period of 2024-2032.

Geographic Distribution

North America: North America holds the largest share of the hepatitis B treatment market due to well-established healthcare infrastructure, high awareness levels, and availability of advanced therapeutic options.

Asia-Pacific: The Asia-Pacific region, which bears a large proportion of global hepatitis B cases, is expected to witness rapid growth due to increased healthcare access and growing awareness.

Europe: Europe is also a significant market for hepatitis B treatments, with growing investment in healthcare and research in the region.

Trends Shaping the Hepatitis B Treatment Market

Several key trends are influencing the hepatitis B treatment market's dynamics:

Adoption of Direct-Acting Antivirals (DAAs): The shift from interferon-based therapies to more effective and easier-to-administer DAAs is one of the major trends driving market growth. DAAs offer better patient compliance due to fewer side effects and shorter treatment regimens.

Focus on Early Diagnosis: With the availability of advanced diagnostic technologies such as rapid tests and nucleic acid testing, early diagnosis of hepatitis B has improved, leading to quicker treatments and better management of the disease.

Research and Development in Vaccine Technology: The development of new hepatitis B vaccines and the focus on combination therapies are key trends expected to revolutionize treatment protocols in the coming years.

Rising Awareness and Government Initiatives: Government-backed vaccination programs and health initiatives in both high- and low-income countries are expanding access to hepatitis B care. These initiatives are expected to support long-term market growth.

Market Growth Drivers

Several factors are driving the growth of the hepatitis B infection treatment market:

Increasing Prevalence of Hepatitis B Infections: As mentioned earlier, the rising global prevalence of hepatitis B is the primary driver of market growth. More people are being diagnosed and treated, leading to a growing demand for effective therapies.

Technological Advancements in Treatment Options: The availability of new treatment options, such as antiviral drugs that can suppress the virus for extended periods, is further expanding the market. Moreover, the integration of combination therapies to enhance therapeutic efficacy is also contributing to market growth.

Improved Diagnostics: Advancements in diagnostic tests, which allow for the early detection of hepatitis B, are encouraging more individuals to seek treatment. Early detection can significantly improve long-term health outcomes.

Government Policies and Vaccination Programs: Several countries are prioritising the fight against hepatitis B through national vaccination campaigns, which are expected to reduce the burden of the disease and drive market expansion.

Challenges Facing the Hepatitis B Treatment Market

Despite its growth potential, the hepatitis B treatment market faces several challenges:

High Treatment Costs: In many countries, the cost of hepatitis B treatment, particularly antiviral therapies, remains high, making it difficult for some populations to afford the necessary care.

Lack of Awareness: While awareness is improving, there are still significant gaps in understanding hepatitis B, particularly in low-income countries. This lack of awareness can lead to delayed diagnoses and treatment, further exacerbating the public health burden.

Resistance to Antiviral Drugs: The growing resistance of the hepatitis B virus to antiviral drugs is a major concern in the treatment landscape. This may require ongoing research into new therapies that can combat resistant strains.

Segments of the Hepatitis B Infection Treatment Market

The hepatitis B treatment market is segmented based on the type of treatment, distribution channel, and region.

By Treatment Type

Antiviral Drugs: Antiviral drugs are the primary treatment for hepatitis B. These drugs can help reduce viral replication, prevent liver damage, and lower the risk of complications. The most commonly used antiviral drugs include nucleoside and nucleotide analogues such as tenofovir and entecavir.

Vaccines: Hepatitis B vaccines have played a crucial role in reducing the spread of the infection. The vaccines have been widely adopted worldwide and are a key preventive measure.

Interferons: Though less commonly used today due to the side effects and long treatment duration, interferons are still part of some hepatitis B treatment regimens, particularly for patients who have not responded to other treatments.

By End-User

Hospitals

Specialty Clinics

Homecare Settings

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

COVID-19 Impact on the Hepatitis B Treatment Market

The COVID-19 pandemic has had a significant impact on healthcare markets across the globe, and the hepatitis B treatment market is no exception. Here's how the pandemic affected the market:

Disruption of Healthcare Services: Due to the strain on healthcare systems caused by COVID-19, many non-COVID treatments, including hepatitis B management, were temporarily sidelined. This led to delays in diagnosis and treatment, particularly in regions severely affected by the pandemic.

Shift Towards Telemedicine: The increased reliance on telemedicine during the pandemic has led to greater acceptance of digital healthcare solutions. This has, in turn, increased the potential for remote consultations and monitoring for hepatitis B patients.

Supply Chain Disruptions: The global disruption of supply chains during the pandemic led to challenges in the availability of antiviral drugs and vaccines. This affected the timely treatment of hepatitis B patients.

Accelerated Vaccine Development: While the focus during the pandemic was largely on COVID-19 vaccines, the urgent need for effective vaccines has catalysed research into vaccines for other diseases, including hepatitis B. The COVID-19 pandemic has shown the power of rapid vaccine development, which may inspire more investment in hepatitis B vaccine research.

Forecast and Outlook (2024-2032)

The hepatitis B infection treatment market is expected to continue its growth trajectory over the forecast period, reaching a value of approximately USD 6.1 billion by 2032. The growing global awareness about hepatitis B, improved healthcare infrastructure, and the ongoing research and development of better treatment options will support the market's growth.

Moreover, the increasing emphasis on hepatitis B vaccination programs, particularly in developing countries, will help reduce the disease burden and contribute to the market's positive outlook.

[global-research-report]

Contrast Enhanced Ultrasound Market Players, Strategies And Outlook Status 2030

The global contrast enhanced ultrasound market is anticipated to reach USD 2.99 billion by 2030. It is projected to grow at a CAGR of 5.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic disorders such as cardiovascular ailments, cancer, and liver disease, growing geriatric population, and increasing technological advancements in the ultrasound imaging technology are the major factors anticipated to boost the contrast-enhanced ultrasound market growth over the forecast period. Growth in the market is further propelled using contrast-enhanced ultrasound over other imaging modalities like CT and MRI has become more popular due to its lower cost, portability, and lack of ionizing radiation.

The rising prevalence of cardiovascular diseases fueling the market growth. According to the World Health Organization (WHO), an estimated 17.9 million deaths occur each year due to cardiovascular diseases, making it the leading cause of death globally. In 2022, it is expected that there will be an increase in the number of people diagnosed with cardiovascular diseases. This is where contrast-enhanced ultrasound (CEUS) can play a crucial role in helping to detect and monitor these conditions. CEUS uses a contrast agent that enhances the ultrasound image, allowing for better visualization of the heart and blood vessels. It can be used to diagnose conditions such as heart valve disease, aortic aneurysm, and peripheral artery disease.

Furthermore, CEUS is a non-invasive and safe imaging modality that does not use ionizing radiation. This makes it a preferred option over other imaging modalities like CT and MRI, which use ionizing radiation. In 2021, a study published in the Journal of the American College of Cardiology showed that CEUS had high diagnostic accuracy in detecting coronary artery disease compared to other imaging modalities. With its many benefits, CEUS is becoming an increasingly important tool in diagnosing and managing cardiovascular diseases.

Contrast Enhanced Ultrasound Market Report Highlights

Based on product, the equipment segment held the largest revenue share in 2023. This can be attributed to the largest installed base of ultrasound imaging technology compatible with CEUS.

The contrast agents segment is expected to grow at the fastest CAGR of 6.32% during the forecast period owing to its approval of usage in the liver and pediatric imaging by the FDA.

Based on type, the non-targeted segment held the largest revenue share in 2023 as most of the commercially available contrast agents are non-targeted in nature.

The hospitals segment held the largest market share in 2023 owing to the increasing number of emergency visits with medical conditions such as abdominal pain, abdominal/thoracic trauma, and cardiac complications

The clinics segment is anticipated to witness lucrative CAGR over the forecast period owing to the realization of economic and patient care benefits with the adoption of sonography devices in practice among physicians at primary and secondary care

In Asia Pacific, the market is expected to grow at the fastest CAGR owing to the limited accessibility to advanced CT/MRI imaging modalities such as CT and MRI, and the growing burden of cardiovascular disorders in China and India.

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global endoscopy visualization systems market size was valued at USD 25.1 billion in 2023 and is projected to grow at a CAGR of 6.8% from 2024 to 2030.

Asia Pacific bone grafts & substitutes market size was estimated at USD 662.4 million in 2024 and is projected to grow at a CAGR of 8.2% from 2025 to 2030.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global contrast enhanced ultrasound market report based on product, type, end-use, and region:

Contrast Enhanced Ultrasound Product Outlook (Revenue, USD Million, 2018 - 2030)

Equipment

Contrast Agents

Contrast Enhanced Ultrasound Type Outlook (Revenue, USD Million, 2018 - 2030)

Non-targeted

Targeted

Contrast Enhanced Ultrasound End-use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals

Clinics

Ambulatory Diagnostic Centers

Contrast Enhanced Ultrasound Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Thailand

Australia

Latin America

Brazil

Mexico

Argentina 

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Order a free sample PDF of the Contrast Enhanced Ultrasound Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

Progressive Pulmonary Fibrosis (PPF) represents a subset of interstitial lung diseases (ILDs) characterized by chronic and progressive scarring of lung tissue, leading to respiratory decline. As the condition progresses, patients experience increasing breathlessness and reduced quality of life. The growing awareness of PPF, coupled with advancements in diagnostics and treatment, has fueled significant growth in the PPF treatment market. This article explores the market landscape, emerging trends, and future opportunities within this domain.

Browse the full report at https://www.credenceresearch.com/report/progressive-pulmonary-fibrosis-ppf-treatment-market

Market Overview

The PPF treatment market is poised for substantial growth, driven by the rising prevalence of fibrotic lung diseases. According to recent data, idiopathic pulmonary fibrosis (IPF) affects approximately 3 million people worldwide, with a significant portion progressing to PPF. Additionally, other forms of ILD, such as chronic hypersensitivity pneumonitis and connective tissue disease-associated ILD, contribute to the disease burden.

The introduction of antifibrotic therapies has transformed the treatment landscape. Medications like pirfenidone and nintedanib, originally developed for IPF, are now being repurposed and studied for their efficacy in treating other forms of PPF. These drugs aim to slow disease progression and improve patient outcomes, though they do not cure the condition.

Key Market Drivers

Rising Disease Awareness: Improved diagnostic capabilities and awareness campaigns have led to earlier identification of PPF, enabling timely intervention. This has driven demand for effective treatments.

Advancements in Research: Significant investment in understanding the underlying mechanisms of fibrosis has accelerated the development of targeted therapies. Research into biomarkers and personalized medicine holds promise for more effective and tailored treatments.

Regulatory Approvals and Guidelines: Regulatory bodies like the FDA and EMA have recognized the need for effective PPF treatments, facilitating faster approval pathways for promising therapies. Updated guidelines emphasizing the role of antifibrotics in PPF management have further supported market growth.

Aging Population: The global aging population is at increased risk of developing ILDs, including PPF, due to cumulative environmental exposures and age-related changes in lung function.

Challenges

Despite its growth potential, the PPF treatment market faces several challenges:

High Cost of Treatment: Antifibrotic drugs are expensive, limiting accessibility for patients in low- and middle-income countries.

Side Effects: The adverse effects associated with current therapies, such as gastrointestinal disturbances and liver toxicity, can impact patient adherence.

Diagnostic Complexity: Differentiating PPF from other lung diseases remains challenging, often delaying treatment initiation.

Emerging Trends

Combination Therapies: Researchers are exploring the potential of combining antifibrotic drugs with immunomodulators or anti-inflammatory agents to enhance efficacy.

Biologics and Gene Therapy: The use of biologics targeting specific pathways involved in fibrosis, such as TGF-beta signaling, is gaining traction. Additionally, gene therapy approaches offer hope for halting or reversing disease progression.

Digital Health Tools: Wearable devices and telemedicine platforms are being integrated into PPF management to monitor disease progression and improve patient outcomes.

Clinical Trials and Collaboration: Pharmaceutical companies are increasingly collaborating with academic institutions and biotech firms to expedite drug discovery and clinical trials.

Future Outlook

The PPF treatment market is on the cusp of transformative growth, underpinned by innovations in drug development and a deeper understanding of disease mechanisms. Strategic partnerships between stakeholders, coupled with supportive regulatory frameworks, are expected to further accelerate market expansion. However, addressing barriers such as high treatment costs and diagnostic delays will be critical to unlocking the full potential of this market.

Key Player Analysis

Bristol-Myers Squibb

FibroGen

Pliant Therapeutics, Inc.

Boehringer Ingelheim

Hoffmann-La Roche Ltd

Merck & Co., Inc.

United Therapeutics Corporation

Novartis AG

Galapagos

Prometic Life Sciences Inc.

Segments:

Based on Treatment Type:

MAPK Inhibitor

Tyrosine Inhibitor

Autotaxin Inhibitors

Based on Distribution Channel:

Hospital Pharmacies

Online Pharmacies

Based on Treatment:

Self-Care

Medicines

Pirfenidone

Nintedanib

Others

Lung Transplant

Palliative Care

Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/progressive-pulmonary-fibrosis-ppf-treatment-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com 

[stephengrand]

Global Rare Haematology Disorders Market Size, Share, Growth, Key Player, Report, Future Forecast, & Outlook | 2024 - 2032

The global rare haematology disorders market is on the rise, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Rare haematology disorders, though uncommon, represent a growing area of concern in the field of healthcare. These disorders typically affect the blood and its components, such as red blood cells, white blood cells, platelets, and plasma. Despite their rarity, they are often associated with severe health complications, making research, diagnosis, and treatment critical.

This article explores the trends, drivers, challenges, and growth opportunities within the rare haematology disorders market. Additionally, we will delve into the key players shaping this market and answer some frequently asked questions (FAQs).

Get a Free Sample Report with Table of Contents

Understanding Rare Haematology Disorders

Rare haematology disorders are a subset of blood-related diseases that occur infrequently in the general population. These conditions are often genetic, congenital, or acquired and can severely impact an individual’s overall health and quality of life. Some examples of rare haematology disorders include:

Haemophilia: A bleeding disorder due to the deficiency of certain clotting factors in the blood.

Sickle Cell Disease: A genetic disorder where red blood cells are abnormally shaped, causing blockages in blood flow.

Thalassemia: A group of inherited blood disorders characterized by abnormal haemoglobin production.

Gaucher’s Disease: A rare inherited metabolic disorder that affects the spleen, liver, and bone marrow.

The global rise in awareness and advancements in medical research are expected to significantly influence the growth of the rare haematology disorders market.

Market Trends and Drivers

Several factors are contributing to the rapid growth of the rare haematology disorders market:

Advances in Medical Research and Treatment Medical advancements are playing a key role in increasing the diagnosis and treatment options for rare haematology disorders. The development of targeted therapies, gene therapies, and more sophisticated diagnostic tools has made it easier to manage these conditions effectively.

Growing Prevalence of Genetic Disorders A rising global prevalence of inherited blood disorders such as haemophilia, thalassemia, and sickle cell disease is propelling the demand for specialized treatment. Governments and non-governmental organizations are also focusing more on improving healthcare for people with these rare conditions.

Increasing Healthcare Expenditure Governments around the world are allocating more resources to improve healthcare systems, especially for underserved populations. This is driving the growth of the rare haematology disorders market as more patients gain access to specialized care.

Focus on Gene and Cell-Based Therapies Ongoing research in gene therapy and stem cell-based treatments has led to innovative ways of treating rare haematology disorders. These therapies have the potential to cure certain genetic disorders, thus driving the market forward.

Rise in Diagnostics and Screening Programs Advances in diagnostics, along with nationwide screening programs for genetic disorders, have led to earlier detection and better management of rare haematology disorders. This has contributed to the overall market growth.

Challenges in the Rare Haematology Disorders Market

Despite the significant growth in the rare haematology disorders market, several challenges persist:

High Cost of Treatments One of the major challenges in the treatment of rare haematology disorders is the high cost of therapies. The rarity of these conditions means that treatment options are often limited and expensive, leading to a significant financial burden on patients and healthcare providers.

Limited Access to Specialized Care Many rare haematology disorders are difficult to diagnose, and there is a lack of specialists available in some regions. This restricts the access of patients to necessary treatment, hindering the overall market potential.

Regulatory Challenges Regulatory approval for new treatments for rare diseases can be slow and complicated. Furthermore, the lack of large patient populations means that conducting clinical trials is more difficult, slowing down the development of new therapies.

Lack of Awareness Awareness of rare haematology disorders is still limited in many parts of the world, leading to underdiagnosis and delayed treatment. This can result in a worse prognosis for patients, increasing the overall burden on the healthcare system.

Opportunities in the Rare Haematology Disorders Market

The rare haematology disorders market is poised to see significant growth over the next decade, with several opportunities for stakeholders to tap into:

Emerging Markets The increasing healthcare infrastructure in emerging markets presents a significant growth opportunity for the rare haematology disorders market. With more patients gaining access to treatment, companies can expand their market reach in these regions.

Collaboration and Partnerships Collaboration between pharmaceutical companies, academic institutions, and research organisations can accelerate the development of new therapies and treatments for rare haematology disorders. This can also help reduce the overall costs of treatment.

Innovation in Drug Development Innovative therapies, including gene therapy, are expected to revolutionise the treatment landscape for rare haematology disorders. Companies focusing on developing these therapies stand to benefit as the demand for more effective treatments increases.

Increased Patient Advocacy As patient advocacy groups gain more traction, there is a growing push for policies that improve treatment access and affordability. This, in turn, could foster market expansion by increasing public awareness and patient enrolment in clinical trials.

Key Players in the Rare Haematology Disorders Market

Several pharmaceutical and biotechnology companies are contributing to the growth of the rare haematology disorders market by developing novel therapies and treatment approaches. Some of the key players include:

Novartis

Headquarters: Basel, Switzerland

Novartis has been a significant player in the rare haematology disorders market, particularly with its gene therapies like Kymriah and therapies for sickle cell disease.

Sanofi

Headquarters: Paris, France

Sanofi’s haemophilia treatment portfolio is extensive, with both preventative and curative therapies available, making them a key player in the rare haematology disorders space.

Pfizer

Headquarters: New York, USA

Pfizer is focused on haemophilia therapies and is continuously expanding its rare blood disorder treatments, aiming for long-term management solutions.

Bristol-Myers Squibb

Headquarters: New York, USA

Bristol-Myers Squibb has recently invested in gene therapies, making them a major contributor to the treatment of rare haematology disorders, particularly in areas like thalassemia.

Amgen

Headquarters: Thousand Oaks, USA

Amgen focuses on the development of novel biologics for the treatment of rare blood disorders, including innovative treatments for blood clotting and immune-related disorders.

Shire (Acquired by Takeda)

Headquarters: Dublin, Ireland

Shire has been a prominent player in the treatment of rare haematology disorders, particularly in haemophilia. It was acquired by Takeda Pharmaceuticals, extending its reach and capabilities in this field.

Roche

Headquarters: Basel, Switzerland

Roche is developing treatments for a range of rare haematology disorders and is involved in providing comprehensive solutions for these conditions globally.

FAQs

What are rare haematology disorders? Rare haematology disorders are uncommon blood-related conditions that can significantly affect health. These include disorders like haemophilia, sickle cell disease, and thalassemia, often requiring specialised treatment.

What are the main factors driving the growth of the rare haematology disorders market? Key drivers include advances in medical research, the growing prevalence of genetic disorders, increasing healthcare expenditure, and the focus on gene and cell-based therapies.

Which are the leading companies in the rare haematology disorders market? Leading companies include Novartis, Sanofi, Pfizer, Bristol-Myers Squibb, Amgen, Shire (now part of Takeda), and Roche, all of which are heavily involved in the development of treatments for rare haematology disorders.

What are the challenges faced by the rare haematology disorders market? The market faces challenges such as the high cost of treatments, limited access to specialised care, regulatory hurdles, and a lack of awareness.

What opportunities exist in the rare haematology disorders market? Opportunities include expanding into emerging markets, partnerships between pharma companies and research institutions, innovations in drug development, and increased patient advocacy.

What is the expected growth rate of the rare haematology disorders market? The global rare haematology disorders market is expected to grow at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2032.

[latestmarketresearchnews]

Urinalysis Market Drivers, Industry Survey and Business Development Analysis till 2030

The global urinalysis market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 4.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of UTI worldwide contributes to market growth. According to a study published by SHEA journal, in 2021, approximately 60% to 70% of urinalyses were being performed in patients without symptoms referable to the Gastrointestinal Tract (GU).

Increasing geriatric population and the subsequent increase in age related diseases in developed and developing regions will positively influence urinalysis market growth. According to the World Health Organization (WHO), the geriatric population increased from 1 billion in 2020 to 1.4 billion in 2021. The early diagnosis and management of chronic diseases in geriatric population is responsible for the increasing prescription rate for tests such as bilirubin, ketones, glucose, and creatinine. These tests are performed by urinalysis; hence, it is anticipated to drive market growth.

Gather more insights about the market drivers, restrains and growth of the Global Urinalysis Market

Moreover, for patients undergoing transplant surgeries including kidney and liver, transplant procedures is often recommended to undergo preoperative urinalysis to avoid urinary tract infections (UTIs). According to United Network for Organ Sharing data, around 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplants were performed in the U.S. in 2021. Thus, an increasing number of transplant surgeries is expected to fuel market growth.

Companies are taking initiatives such as collaboration and strategic partnerships for the development and marketing of technologically advanced urinalysis products. For instance, in October 2021, Sysmex entered into collaboration with Inpeco for the development of an automated urinalysis workflow solution of the highest level. This product was developed with a help of UN-Series of Sysmex's and FlexLab TM track of Inpeco’s urinalysis solutions. It is the only fully open automation system that helps laboratories optimize their workflow support and provide premium patient care.

Urinalysis Market Report Highlights

Based on product, the consumables segment held the largest share market in 2022 due to wider usage of dipsticks due to their efficiency coupled with lost costs

Based on application, the disease screening segment accounted for the largest segment, owing to the increasing prevalence of target diseases such as UTI, kidney disease, and liver disease, along with the rising application of urinalysis for screening of these diseases

On the basis of end-use, the clinical laboratories segment dominated the market in 2022 owing to higher patient footfall in clinical laboratories for urine testing for disease diagnosis

Home care segment is expected to witness significant growth over the forecast period owing to increasing investment for the development of home-based urine testing kits for disease diagnosis

North America segment dominated the market in 2022 due to favorable reimbursement policies, rising incidence of UTI, well-established healthcare infrastructure, and supportive regulatory reforms

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

Body Fluid Collection And Diagnostics Market: The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030.

Genetic Testing Market: The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is projected to grow at a CAGR of 22.5% from 2025 to 2030.

Urinalysis Market Segmentation

Grand View Research has segmented the global urinalysis market based on product, application, end-use, and region:

Urinalysis Product Outlook (Revenue, USD Million, 2018 - 2030)

Instrument

Biochemical urine analyzers

Automated biochemical analyzers

Semi-automated biochemical analyzers

Automated urine sediment analyzers

Microscopic urine analyzers

Flow-cytometric urine analyzers

Point-of-care urine analyzers

Consumables

Dipsticks

Reagents

Disposables

Pregnancy and fertility kits

Urinalysis Application Outlook (Revenue, USD Million, 2018 - 2030)

Disease Screening

UTIs

Diabetes

Kidney disease

Hypertension

Liver disease

Others

Pregnancy and Fertility Testing

Urinalysis End-use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals

Clinical Laboratories

Home Care

Research and Academics

Others

Urinalysis Regional Outlook (Revenue, USD Million, 2018 - 2030) 

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Order a free sample PDF of the Urinalysis Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

Urinalysis Market Growth Opportunities and Trends by Leading Manufacturers 2030

The global urinalysis market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 4.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of UTI worldwide contributes to market growth. According to a study published by SHEA journal, in 2021, approximately 60% to 70% of urinalyses were being performed in patients without symptoms referable to the Gastrointestinal Tract (GU).

Increasing geriatric population and the subsequent increase in age related diseases in developed and developing regions will positively influence urinalysis market growth. According to the World Health Organization (WHO), the geriatric population increased from 1 billion in 2020 to 1.4 billion in 2021. The early diagnosis and management of chronic diseases in geriatric population is responsible for the increasing prescription rate for tests such as bilirubin, ketones, glucose, and creatinine. These tests are performed by urinalysis; hence, it is anticipated to drive market growth.

Gather more insights about the market drivers, restrains and growth of the Global Urinalysis Market

Moreover, for patients undergoing transplant surgeries including kidney and liver, transplant procedures is often recommended to undergo preoperative urinalysis to avoid urinary tract infections (UTIs). According to United Network for Organ Sharing data, around 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplants were performed in the U.S. in 2021. Thus, an increasing number of transplant surgeries is expected to fuel market growth.

Companies are taking initiatives such as collaboration and strategic partnerships for the development and marketing of technologically advanced urinalysis products. For instance, in October 2021, Sysmex entered into collaboration with Inpeco for the development of an automated urinalysis workflow solution of the highest level. This product was developed with a help of UN-Series of Sysmex's and FlexLab TM track of Inpeco’s urinalysis solutions. It is the only fully open automation system that helps laboratories optimize their workflow support and provide premium patient care.

Urinalysis Market Report Highlights

Based on product, the consumables segment held the largest share market in 2022 due to wider usage of dipsticks due to their efficiency coupled with lost costs

Based on application, the disease screening segment accounted for the largest segment, owing to the increasing prevalence of target diseases such as UTI, kidney disease, and liver disease, along with the rising application of urinalysis for screening of these diseases

On the basis of end-use, the clinical laboratories segment dominated the market in 2022 owing to higher patient footfall in clinical laboratories for urine testing for disease diagnosis

Home care segment is expected to witness significant growth over the forecast period owing to increasing investment for the development of home-based urine testing kits for disease diagnosis

North America segment dominated the market in 2022 due to favorable reimbursement policies, rising incidence of UTI, well-established healthcare infrastructure, and supportive regulatory reforms

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

Body Fluid Collection And Diagnostics Market: The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030.

Genetic Testing Market: The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is projected to grow at a CAGR of 22.5% from 2025 to 2030.

Urinalysis Market Segmentation

Grand View Research has segmented the global urinalysis market based on product, application, end-use, and region:

Urinalysis Product Outlook (Revenue, USD Million, 2018 - 2030)

Instrument

Biochemical urine analyzers

Automated biochemical analyzers

Semi-automated biochemical analyzers

Automated urine sediment analyzers

Microscopic urine analyzers

Flow-cytometric urine analyzers

Point-of-care urine analyzers

Consumables

Dipsticks

Reagents

Disposables

Pregnancy and fertility kits

Urinalysis Application Outlook (Revenue, USD Million, 2018 - 2030)

Disease Screening

UTIs

Diabetes

Kidney disease

Hypertension

Liver disease

Others

Pregnancy and Fertility Testing

Urinalysis End-use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals

Clinical Laboratories

Home Care

Research and Academics

Others

Urinalysis Regional Outlook (Revenue, USD Million, 2018 - 2030) 

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Order a free sample PDF of the Urinalysis Market Intelligence Study, published by Grand View Research.

[marketsndata]

Global Preeclampsia Diagnostics Market Size, Share, Growth and Forecast 2031

Global preeclampsia diagnostics market is projected to witness a CAGR of 3.23% during the forecast period 2024-2031, growing from USD 1077.00 million in 2023 to USD 1388.87 million in 2031. The market demand for preeclampsia diagnostic products is anticipated to rise in the forecast period due to the increased prevalence of preeclampsia, rising awareness of women’s health safety, and various technological advancements that contribute to the growth of the market.

Preeclampsia, also known as Toxemia, is a multi-system disorder that is specific to pregnancy and is characterized by the new onset of high blood pressure, often with significant amounts of protein in the urine, or by the new onset of high blood pressure along with a significant end-organ damage, the disorder might occur with or without the proteinuria. When the condition appears, it starts at 20 weeks of gestation. In more severe stages of the disease, there can also be red blood cell breakdown and low levels of blood platelets, as well as dysfunction of the liver, kidney insufficiency, edema, shortness of breath due to pulmonary edema, or visual disturbance. Pre-eclampsia is diagnosed as a hypertensive disorder of pregnancy; its global prevalence is approximately 1–5% of pregnancies, and this condition is recognized to be one of the leading causes of maternal mortality.

Hypertensive disorders of pregnancy (including pre-eclampsia) are the second most frequent cause of death in maternity-related cases all over the world and are estimated to result in 62,000–77,000 deaths each year. Rising awareness about this disorder and its diagnostic procedure in pregnant women are anticipated factors for the growth of the preeclampsia diagnostic market in the forecast period. For instance, on 19 May 2023, Thermo Fisher Scientific Inc. announced its approval from the U.S. Food and Drug Administration (USFDA) for the first blood test to predict preeclampsia in pregnant women. This blood test is meant for women in their 23rd to 35th weeks of pregnancy.

Increasing Prevalence of Preeclampsia to Drive Market Growth

The increasing incidence of preeclampsia is a major growth factor for the preeclampsia diagnostics market. Factors contributing to the increase include more pregnancies among older women who are at higher risk of developing preeclampsia and lifestyles that have led to obesity and chronic conditions such as diabetes and hypertension. Increased access and availability of prenatal care compounds and socioeconomic factors lead to a high percentage of conditions being undiagnosed or poorly treated. An increase in knowledge about preeclampsia and its life-threatening complications has led to more aggressive action from healthcare providers to screen and monitor the condition early in pregnancy, stressing the need for early intervention to avoid poor outcomes for the mother and child. This increasing prevalence calls for the need to find effective ways of preventing preeclampsia and ensuring healthier pregnancies. For instance, on 31 May 2023, CSEM announced a collaboration with MOMM Diagnostics to develop a cutting-edge point-of-care solution for preeclampsia diagnostics.

Technological Advancements to Drive the Preeclampsia Diagnostics Market Growth

Technological advancements are a key driver for the growth of the preeclampsia diagnostic market as they change how practitioners diagnose and manage this life-threatening condition. Based on innovation, research into biomarkers has led to tests that are sensitive and specific enough to enable the diagnosis of preeclampsia earlier and with greater accuracy than in the past. Moreover, advancements in imaging technologies such as ultrasound and Doppler assessments make it increasingly easier to check fetal well-being and placental health. Integrating artificial intelligence and machine learning makes predictive analytics more personalized about risk, enabling selective interventions. These technological improvements would make the diagnostic process faster and enable healthcare professionals to make more informed decisions, ultimately leading to better maternal and fetal health outcomes. For instance, on 23 September 2024, Unitaid published a report on tools and interventions for the diagnosis and management of pre-eclampsia. The report identifies several new diagnostic tools with promise, holding out the prospect of identifying a woman’s risk of contracting pre-eclampsia or even the worsening of the condition. There are two blood biomarker-based SFlt-1 tests, and the placental growth factor can easily be adapted for low-resource settings and further improve treatment options for women diagnosed with a risk of preeclampsia.

Testing Segment to Dominate the Preeclampsia Diagnostics Market Share

The testing segment is expected to dominate the market throughout the forecast period due to its key role in early diagnosis and management of the disease. Increasing numbers of testing modalities, such as blood tests for biomarkers soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF) levels and urine tests to determine protein levels, are routinely offered during the standard prenatal care process. Such tests will help healthcare providers identify the risks patients face and provide early intervention time that would improve their maternal and fetal health. Other than this, personalized medicine has resulted in the formulation of testing protocols that are gradually designed and tailored to the risk profile of individuals. As education about preeclampsia disseminates and healthcare providers increasingly adopt these advanced technologies for testing, the demand for innovative, time-saving diagnostic solutions will continue to increase. For instance, in July 2022, PerkinElmer, Inc., a global leader in innovation, announced that a placental growth factor (PlGF) measurement using its DELFIA Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA Xpress sFlt-1 kit (CE-IVD), have been included in updated diagnostic guidance issued by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm pre-eclampsia.

North America Dominates the Preeclampsia Diagnostics Market Share

North America dominates the share of the preeclampsia diagnostics market, driven by a combination of advanced healthcare infrastructure with higher levels of awareness, along with significant investment in research. Preeclampsia is a pregnancy-specific disease that affects 2-8% of all pregnancies and is the most significant cause of morbidity and mortality among mothers and neonates in the United States. It has well-established healthcare providers with state-of-the-art diagnostic technologies, thus allowing for relatively prompt and accurate identification of cases of preeclampsia. Another driving force behind the demand for effective diagnostic solutions is the growing attention to antenatal care and early intervention, coupled with governmental efforts to improve maternal health outcomes. The rising prevalence of risk factors such as obesity and advanced maternal age in North America also contributes to the increase in the prevalence of preeclampsia. With a high emphasis on keeping the mother’s health as the top priority, it is found that North America still dominates the preeclampsia diagnostics market. For instance, on 31 January 2024, LabCorp, a global leader in innovative and comprehensive laboratory services, announced the US Food and Drug Administration’s approval for blood tests for risk assessment and clinical management of severe preeclampsia.

Download Free Sample Report

Future Market Scenario (2024-2031F)

The future market scenario of the preeclampsia diagnostics market appears quite promising because of ongoing technological advancements and the growing interest in maternal health. Continued research to identify new biomarkers and methodologies for testing improve diagnostics substantially in terms of accuracy and reliability. Predictive analytics based on artificial intelligence and machine learning approaches can facilitate more personalized and proactive management approaches in risk management for preeclampsia. It will increase awareness of primary caregivers and expectant mothers for earlier interventions. It opens new market opportunities for new therapeutic interventions and better diagnostics to change the matrix of maternal care, facilitating improved results for mother and child. As health systems worldwide move forward and focus on more prenatal care than ever, the preeclampsia diagnostics market will grow in the forecast years due to innovation, collaboration, and a goal towards improved standards in maternal health. For instance, in August 2024, ARUP Laboratories announced its Food and Drug Administration approval for blood-based biomarkers tests to assess risk for preeclampsia. This test quantitates the ratio between two angiogenic factors released by the placenta implicated in the pathophysiology of preeclampsia.

Report Scope

“Preeclampsia Diagnostics Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global preeclampsia diagnostics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/preeclampsia-diagnostics-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[insightsresearch]

Idiopathic Pulmonary Fibrosis Treatment Market Outlook and Forecasts By Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis

Idiopathic Pulmonary Fibrosis Treatment Market Size by Research Nester Reveals the Market to Grow with a CAGR of 7.1% During 2025-2037 and Attain USD 7.9 Billion by 2037

Research Nester assesses the growth and market size of global idiopathic pulmonary fibrosis treatment market which is anticipated to be on account of the rising awareness about IPF and ILD, among healthcare practitioners and patients as well.

Research Nester’s recent market research analysis on “Idiopathic Pulmonary Fibrosis Treatment Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor’s analysis and a detailed overview of the global idiopathic pulmonary fibrosis treatment market in terms of market segmentation by treatment type, route of administration, age group, end use, and by region.

Increasing Incidence and Prevalence of Idiopathic Pulmonary Fibrosis to Promote Global Market Share of Idiopathic Pulmonary Fibrosis Treatment

According to the NLM[AD1] , idiopathic pulmonary fibrosis treatment accounts for 17–37% of all cases of interstitial lung disease (ILD) and accounts for the maximum recurrent and severe idiopathic interstitial pneumonias (IIPs). It is an expensive disease with treatment costs of around USD 25,000 per person, every year. The growing patient population directly correlates with an increased demand for effective treatments, thereby driving market growth.

Additionally, greater recognition of IPF among healthcare providers leads to earlier intervention and management. It gives rise to improved diagnostic capabilities, and more cases being identified, particularly among the aging population, further propelling the idiopathic pulmonary fibrosis treatment market expansion with new product launches. For instance, in February 2022, Boehringer Ingelheim [AD2] received U.S. FDA Breakthrough Therapy Designation BI 1015550, a novel investigational therapy, for the treatment of IPF.

Some of the major growth factors and challenges that are associated with the growth of the global idiopathic pulmonary fibrosis treatment market are:

Growth Drivers:

Rising focus on Quality-of-Life (QoL) Studies

Development of Antifibrotic Combinations

Challenges:

While antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow disease progression, their effects are often modest, leading to a need for more effective options. Additionally, these medicines can cause side effects including gastrointestinal issues, fatigue, and liver function abnormalities, which may deter patient adherence and impact the overall quality of life. This as a result hampers optimal patient management and underscores the urgent need for novel therapies offering improved efficacy with better tolerability.

Access our detailed report at: https://www.researchnester.com/reports/idiopathic-pulmonary-fibrosis-treatment-market/6636

By age group, the global idiopathic pulmonary fibrosis treatment market is segmented into adult and geriatric. The adult segment is anticipated to garner the highest revenue by the end of 2037 by growing at a significant CAGR over the forecast period.  IPF primarily affects individuals aged 50 and above. This demographic is at a higher risk owing to age-related decline in lung function and a higher likelihood of comorbidities that can exacerbate respiratory issues. Lifestyle factors such as smoking history, occupational exposures, and environmental pollutants prevalent among this section of the population further increase their risks of developing IPF.

By region, the Europe idiopathic pulmonary fibrosis treatment market is to generate considerable revenue by the end of 2037. The major drivers include advanced medical infrastructure and supportive regulatory frameworks. The region’s market also benefits from increasing awareness and early diagnosis of the disease. Furthermore, the adoption of telemedicine enabling remote patient monitoring which is vital for managing progressive diseases such as IPF is also thriving. This is further projected to boost the region’s market growth significantly.

Customized report@ https://www.researchnester.com/customized-reports-6636

This report also provides the existing competitive scenario of some of the key players of the market, including Bumrungrad International Hospital, Cedars-Sinai, Cleveland Clinic, Bristol-Myers Squibb Company, Cipla Inc., FibroGen, Inc., Galapagos NV, and others.

Request Report Sample@ https://www.researchnester.com/sample-request-6636

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[cityxray]

Finding an Ultrasound Test Near You: What to Expect and How to Choose the Right Facility

If you’re looking for an “ultrasound test near me,” you’re not isolated. Ultrasound imaging has evolved into one of the most generally used diagnostic tools in healthcare, offering a safe, non-invasive way to view the body. Whether you’re pregnant, marketing with a medical situation, or sharing unexplained signs, an ultrasound test delivers clear pictures of organs, tissues, and blood flow. Here’s what you ought to learn about discovering and training for an ultrasound test about you.

What is an Ultrasound Test?

An ultrasound test, also known as sonography, utilizes high-frequency sound locks to create real-time pictures of systems within the body. Unlike X-rays, which use radiation, ultrasounds are typically safe and can be used repeatedly. This makes them ideal for various uses, including monitoring fetal growth during gestation, diagnosing diseases involving the liver, kidneys, and other organs, and guiding systems like biopsies.

How to Find an Ultrasound Test Near You

Research Online: The easiest way to find an ultrasound building nearby is by exploring online. Keywords like “ultrasound test near me” will provide a list of nearby imaging centers, clinics, and clinics that offer these services. Check websites, ratings, and reviews to ensure you’re choosing a respected facility.

Ask Your Doctor for Recommendations: Your physician can often supply referrals to trusted ultrasound providers. They might also advise on what type of ultrasound is best suited for your specific requirements, as some hospitals may specialize in certain types of ultrasounds, like obstetric or vascular.

Check Insurance and Cost: Make sure the facility accepts your insurance or offers affordable rates for self-paying patients. Ultrasound prices vary depending on the type of test and location, so it’s important to confirm these details in advance.

What to Expect During an Ultrasound Test

Ultrasound tests are quick and easy. During the test, a technician applies a gel on the skin and uses a device called a transducer to send sound waves into the body. These sound waves bounce around, making images of the inner systems on a monitor. Most ultrasound exams take about 30 to 45 minutes.

Why Choosing the Right Facility Matters

When it comes to diagnostic imaging, quality matters. Choosing a respected ultrasound center ensures accurate results and reliable service. Look for accredited facilities with experienced radiologists and advanced equipment, as this can make a significant difference in the accuracy of your diagnosis and therapy.

Final Thoughts

Probing for an “ultrasound test near me” is the first step in taking charge of your health. By choosing a trusted facility, preparing for the test, and knowing what to expect, you can make the procedure smooth and stress-free. Whether for regular monitoring or diagnosing a new condition, an ultrasound test is a useful tool in modern medicine.

[farmacuticals]

Market Dynamics in Veterinary Chemistry Analyzers: Current Demand and Competitive Landscape

A Veterinary Chemistry Analyzer is a specialized diagnostic tool that assists veterinarians in assessing the health and diagnosing diseases in animals by analyzing their blood and other bodily fluids. This advanced technology allows for precise, rapid, and reliable results, which play a crucial role in animal healthcare. Veterinary Chemistry Analyzers are designed to measure various biochemical parameters, such as glucose, liver enzymes, blood urea nitrogen (BUN), and electrolytes, among others, to assess the functionality of vital organs in animals. The data collected helps veterinarians make informed decisions regarding treatments, interventions, and preventive care measures, improving the overall quality of animal healthcare.

The Veterinary Chemistry Analyzer Market Size was projected to reach 2.06 (USD Billion) in 2022 based on MRFR analysis. By 2032, the veterinary chemistry analyzer market is projected to have grown from 2.15 billion USD in 2023 to 3.2 billion USD. Over the course of the forecast period (2024–2032), the Veterinary Chemistry Analyzer Market is anticipated to develop at a CAGR of approximately 4.53%.

Veterinary Chemistry Analyzer Share

The Veterinary Chemistry Analyzer market has seen notable growth in recent years. With the increased awareness of animal health and the rising demand for early disease detection in animals, veterinary clinics and hospitals worldwide are incorporating these analyzers into their practices. North America currently holds the largest Veterinary Chemistry Analyzer Share, with Europe and Asia-Pacific following closely. This market distribution is driven by advanced veterinary practices, a higher pet adoption rate, and growing investments in animal health infrastructure. Analyzers are widely used not only for domestic pets but also for livestock and zoo animals, further contributing to the market share.

Veterinary Chemistry Analyzer Analysis

Veterinary Chemistry Analyzer Analysis provides insights into the functionalities, features, and efficiency of various analyzers on the market. Current analysis indicates a shift towards analyzers that offer ease of use, compactness, and rapid processing capabilities. Analyzers with point-of-care testing (POCT) features are becoming increasingly popular as they allow for immediate, on-site diagnostics, reducing the time needed for sample processing. These analyzers come equipped with user-friendly interfaces and can perform multiple tests simultaneously. A thorough Veterinary Chemistry Analyzer Analysis can guide buyers in selecting analyzers based on parameters like accuracy, speed, compatibility with different species, and affordability, helping veterinarians make informed purchasing decisions.

Veterinary Chemistry Analyzer Trends

There are several Veterinary Chemistry Analyzer Trends shaping the future of this market. First, the integration of advanced technology, such as artificial intelligence (AI) and machine learning, is allowing for enhanced data analysis and interpretation, leading to more accurate diagnoses. Second, portable analyzers are becoming increasingly popular, enabling veterinarians to conduct tests in field settings or at animal shelters. Third, the trend toward environmentally sustainable devices is encouraging manufacturers to develop analyzers with reduced waste output and energy-efficient designs. Fourth, cloud connectivity is becoming a significant feature, enabling veterinarians to store, access, and share data seamlessly. Lastly, analyzers capable of processing smaller sample volumes are trending, as they cause minimal discomfort to animals, making them suitable for all animal sizes, from small pets to large livestock.

Reasons to Buy the Reports on Veterinary Chemistry Analyzers

Comprehensive Insights: Reports on Veterinary Chemistry Analyzers provide in-depth insights into the latest technologies, market demands, and trends, assisting potential buyers in selecting the best analyzer for their needs.

Competitive Analysis: These reports offer competitive analysis by evaluating different manufacturers, models, and features, enabling buyers to understand market positioning and quality comparisons.

Cost-Effectiveness: By providing a detailed cost-benefit analysis, reports can help buyers make financially sound decisions that maximize value without compromising on quality.

Regulatory Compliance: Many reports include information on compliance with industry standards and regulations, ensuring that buyers choose products that meet veterinary healthcare requirements.

Future Market Projections: Reports highlight future market trends and developments, helping buyers make forward-thinking decisions and investments in technology that align with future industry directions.

Recent Developments in Veterinary Chemistry Analyzers

The Veterinary Chemistry Analyzer market has seen numerous recent developments. Manufacturers are continually improving analyzer accuracy, speed, and user-friendliness. AI-powered diagnostic software has emerged, allowing for automated interpretations that assist veterinarians with data analysis. The development of portable analyzers suitable for on-the-go use has made it easier for veterinarians to perform tests in varied settings. Additionally, integration with electronic health records (EHR) is becoming more common, allowing for efficient data management and storage. Finally, many companies are focusing on sustainable design improvements, such as reusable testing cartridges and reduced power consumption, meeting the demand for eco-friendly solutions in veterinary diagnostics

exocrine pancreatic insufficiency treatment market

gene editing tool market

handheld ultrasound market

[harshnews]

Viral Hepatitis Market Size, Share, Trends, Growth and Competitive Outlook

"Viral Hepatitis Market – Industry Trends and Forecast to 2029

Global Viral Hepatitis Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others), Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others), Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- **Type:** The market can be segmented based on the type of viral hepatitis, including hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. Each type presents unique challenges and opportunities in terms of treatment and prevention strategies.

- **Treatment:** Another key segment is based on treatment options for viral hepatitis, which can include antiviral medications, immunomodulators, and liver transplant. The effectiveness of treatments varies depending on the type and stage of hepatitis.

- **End-User:** The market can also be segmented by end-users, such as hospitals, clinics, diagnostic centers, and research institutions. Each segment has different demands for viral hepatitis products and services, driving the market in various directions.

**Market Players**

- **Gilead Sciences, Inc.:** An established player in the viral hepatitis market, Gilead Sciences is known for its innovative treatments for hepatitis C, such as Sovaldi and Harvoni. The company continues to invest in research and development to address the evolving needs of patients with viral hepatitis.

- **AbbVie Inc.:** Another major player, AbbVie, has a strong presence in the hepatitis C market with drugs like Viekira Pak. The company's focus on developing effective and accessible treatments has positioned it as a key player in the market.

- **GlaxoSmithKline plc:** GlaxoSmithKline has a significant portfolio of vaccines, including those for hepatitis A and hepatitis B. The company's commitment to preventive healthcare plays a crucial role in shaping the viral hepatitis market.

- **Merck & Co., Inc.:** Merck is renowned for its hepatitis B vaccines, such as Recombivax HB and Engerix-B. The company's long-standing expertise in vaccine development is a cornerstone of its leadership in the viral hepatitis market.

- **Bristol-Myers Squibb Company:** Bristol-Myers Squibb offers treatments for hepatitis B and hepatitis CThe viral hepatitis market is a dynamic and ever-evolving industry with several key players driving innovation, research, and treatment options. Gilead Sciences, Inc. stands out with its pioneering treatments for hepatitis C, including Sovaldi and Harvoni, which have revolutionized the landscape of hepatitis C management. The company's strong emphasis on research and development ensures that it remains at the forefront of developing novel therapies to address the unmet needs of patients with viral hepatitis. Moreover, Gilead's strategic partnerships and collaborations further bolster its position in the market, enabling it to expand its reach globally and diversify its product portfolio.

AbbVie Inc. is another significant player in the viral hepatitis market, particularly excelling in hepatitis C treatments with drugs like Viekira Pak. The company's commitment to innovation and patient-centric approaches has propelled its growth and market presence. AbbVie's focus on developing effective and accessible therapies underscores its dedication to improving outcomes for patients with viral hepatitis, making it a formidable competitor in the industry.

GlaxoSmithKline plc has established itself as a key player in the viral hepatitis market through its robust portfolio of vaccines, including those for hepatitis A and hepatitis B. The company's strong emphasis on preventive healthcare aligns with the global efforts to combat viral hepatitis through vaccination programs and public health initiatives. GlaxoSmithKline's strategic investments in research and development continue to drive advancements in hepatitis prevention and treatment, cementing its position as a leading player in the market.

Merck & Co., Inc. is renowned for its expertise in vaccine development, particularly in hepatitis B vaccines such as Recombivax HB and Engerix-B. The company's longstanding commitment to public health and disease prevention has positioned it as a trusted partner in the fight against viral hepatitis. Merck's focus on innovation, safety, and efficacy of its products underscores its dedication to meeting the evolving needs of patients and healthcare providers in the viral hepatitis market.

Bristol-Myers Squ**Segments**

- **Global Viral Hepatitis Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others):** The viral hepatitis market can be segmented based on the specific type of hepatitis, including hepatitis A, hepatitis B, hepatitis C, and other less common types. Each type presents unique challenges and opportunities for treatment and prevention strategies, driving the demand for targeted solutions in the market.

- **Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others):** Another crucial segment is based on treatment options for viral hepatitis, including antiviral drugs, vaccines, immune modulator drugs, surgical interventions, and other emerging therapies. The availability and effectiveness of these treatment modalities influence the overall market dynamics and patient outcomes.

- **Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others):** The market can also be segmented by diagnostic methods for viral hepatitis, such as liver biopsy, blood tests (including serology and molecular tests), imaging tests (ultrasound, MRI, CT scan), and other diagnostic tools. Accurate and timely diagnosis plays a critical role in guiding treatment decisions and patient management.

- **Route of Administration (Oral, Parenteral, Others):** Another aspect of segmentation is based on the route of administration for hepatitis treatments, including oral medications, injectable (parenteral) formulations, and other delivery methods. The convenience and efficacy of the administration route can influence patient compliance and treatment outcomes

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Key Coverage in the Viral Hepatitis Market Report:

Detailed analysis of Viral Hepatitis Market by a thorough assessment of the technology, product type, application, and other key segments of the report

Qualitative and quantitative analysis of the market along with CAGR calculation for the forecast period

Investigative study of the market dynamics including drivers, opportunities, restraints, and limitations that can influence the market growth

Comprehensive analysis of the regions of the Viral Hepatitis industry and their futuristic growth outlook

Competitive landscape benchmarking with key coverage of company profiles, product portfolio, and business expansion strategies

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[industrynewsupdates]

Blood Screening Market Key Companies, Growth and Forecast Report, 2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030. 

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. 

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

The Pulmonary Arterial Hypertension (PAH) Treatment Market is poised for steady growth, projected to expand from USD 5,820 million in 2024 to approximately USD 6,926.76 million by 2032, with a CAGR of 2.2% during the forecast period. Pulmonary Arterial Hypertension (PAH) is a rare but serious condition characterized by elevated blood pressure in the pulmonary arteries, leading to increased strain on the heart. Over the years, significant advancements in PAH diagnosis and treatment have driven the growth of the global PAH treatment market. The market is witnessing notable expansion due to factors such as increasing prevalence, advancements in therapeutics, and a surge in awareness initiatives.

Browse the full report at https://www.credenceresearch.com/report/pulmonary-arterial-hypertension-pah-treatment-market

Market Overview

The global PAH treatment market is projected to grow at a compound annual growth rate (CAGR) of 5.8% between 2023 and 2030, fueled by technological advancements in drug development and improved diagnostic methods. The rising geriatric population and an increase in conditions like connective tissue diseases, congenital heart diseases, and HIV infections—risk factors for PAH—further augment the market's growth.

Key stakeholders in this market include pharmaceutical companies, healthcare providers, and regulatory bodies. The market is categorized into different segments, such as drug classes, distribution channels, and regions. Leading drug classes include endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5i), and prostacyclin analogs, among others.

Drivers of Growth

Innovative Therapeutics: The PAH treatment market has witnessed a steady influx of innovative drugs that target the underlying pathology of the disease. Combination therapies, involving two or more drug classes, are gaining traction due to their superior efficacy in managing symptoms and slowing disease progression.

Growing Awareness: Governments and non-governmental organizations are increasingly investing in awareness campaigns to educate patients and healthcare professionals about early diagnosis and treatment options. This has led to a rise in demand for PAH therapeutics.

Robust R&D Activities: Pharmaceutical companies are investing heavily in research and development to discover novel drugs and improve existing treatment regimens. The pipeline for PAH drugs remains strong, with several promising candidates in late-stage clinical trials.

Expansion of Healthcare Infrastructure: Improved healthcare infrastructure, especially in emerging economies, has made advanced PAH treatments more accessible, boosting market growth.

Challenges

Despite its promising growth trajectory, the PAH treatment market faces several challenges:

High Cost of Treatment: PAH medications are often expensive, and the cost of long-term treatment can be prohibitive, particularly in low- and middle-income countries.

Adverse Side Effects: Many PAH drugs are associated with side effects such as nausea, dizziness, and liver dysfunction, which may impact patient adherence.

Limited Awareness in Developing Regions: While awareness campaigns are improving, a significant portion of the global population remains unaware of PAH symptoms and treatment options, leading to delayed diagnosis and treatment.

Competition from Generics: The expiration of patents for key PAH drugs has paved the way for generic alternatives, which, while cost-effective, could reduce the profitability of branded drugs.

Future Outlook

The future of the PAH treatment market looks promising, with the potential for significant breakthroughs in personalized medicine. Advances in genetic research may pave the way for targeted therapies that address the disease at its molecular roots. Moreover, digital health technologies, including remote patient monitoring and AI-driven diagnostics, are expected to enhance the management of PAH.

Key Player Analysis:

Johnson & Johnson

Bayer AG

United Therapeutics Corporation

Gilead Sciences, Inc.

Pfizer Inc.

GlaxoSmithKline plc

Actelion Pharmaceuticals (a Janssen company)

Merck & Co., Inc.

Arena Pharmaceuticals, Inc.

Acceleron Pharma Inc.

Segmentations:

By Drug Class:

Prostacyclin & Prostacyclin Analogs

Endothelin Receptor Antagonists (ERAs)

Phosphodiesterase-5 (PDE-5) Inhibitors

Soluble Guanylate Cyclase (sGC) Stimulators

By Pipeline Analysis:

Early-stage Drug Candidates (Phase I & Phase II)

Late-stage Drug Candidates (Phase III & Registration Phase)

By Region:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/pulmonary-arterial-hypertension-pah-treatment-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com